Amgen Inc. vs Canon Inc.: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Canon Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Canon Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Canon Inc. is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against ~$31B for Canon Inc., while their respective market capitalizations stand at $228.2B and $25.6B. Amgen Inc. is headquartered in United States and Canon Inc. in Japan, and those different home markets shape how each company competes.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

Canon Inc.: Canon is a diversified Japanese manufacturer organized into four business units. Printing (office multifunction devices, laser and inkjet printers, production presses) is the largest. Imaging includes EOS cameras, RF lenses, cinema cameras and Axis network cameras. Medical, built on the 2016 purchase of Toshiba Medical Systems, makes CT, MRI, ultrasound and X-ray equipment. Industrial supplies semiconductor and flat-panel lithography tools and Canon Tokki OLED deposition systems. The group had 321 consolidated subsidiaries and 165,547 employees at the end of 2025, and its shares trade on the Tokyo Stock Exchange under code 7751.

Amgen Inc. and Canon Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Canon Inc..

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

Canon Inc. business model: Canon designs, builds and sells hardware, then earns recurring revenue from consumables, service contracts and software on the installed base. In 2025 the Printing Business Unit produced ~$16.7 billion (¥2,494.4 billion) of sales (54%), split between office multifunction devices (~$7.13 billion (¥1,063.7 billion)), prosumer laser and inkjet printers (~$6.66 billion (¥993.4 billion)) and production presses (~$2.93 billion (¥437.3 billion)); toner, ink and maintenance on machines already in the field account for much of that income. Imaging (~$7.07 billion (¥1,054.9 billion), 23%) covers EOS cameras and lenses (~$4.19 billion (¥625.5 billion)) plus network cameras and video software from Axis and Milestone (~$2.88 billion (¥429.4 billion)). Medical (~$3.89 billion (¥580.6 billion), 13%) sells CT, MRI, ultrasound and X-ray systems and service. Industrial (~$2.42 billion (¥361.1 billion), 8%) sells semiconductor and flat-panel lithography tools, Canon Tokki OLED deposition systems and sputtering equipment. Canon sells through regional companies such as Canon U.S.A., Canon Europe and Canon Marketing Japan, and spent ~$2.27 billion (¥339.3 billion), about 7.3% of sales, on R&D in 2025.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Canon Inc..

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Canon Inc. competitive advantage: Canon's edge is vertical integration in optics and imaging. It designs its own lenses, CMOS image sensors, print engines and image-processing chips, and builds much of its own production equipment. That depth shows in its patent output (seventh in U.S. patent grants in 2025 and in the top 10 for 42 straight years, according to IFI Claims) and in a camera business that has held the No. 1 interchangeable-lens share for 23 consecutive years. In printing, a large installed base of office devices produces recurring toner and service revenue that new entrants cannot easily copy.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Canon Inc. each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

Canon Inc. growth strategy: Phase VII sets 2030 sales targets for each unit: Printing ~$18.8 billion (¥2.8 trillion) (about 2% a year), Imaging ~$8.98 billion (¥1.34 trillion) (5%), Medical ~$5.03 billion (¥750 billion) (5%) and Industrial ~$4.02 billion (¥600 billion) (10%). Growth products named in the plan are nanoimprint lithography, photon-counting CT and industrial printing equipment. Canon merged Canon Medical Systems' operations into Canon Inc. on April 1, 2026, is taking Canon Electronics private to build a space business worth ~$134 million (¥20 billion) or more in sales by 2030, and wants emerging markets such as India, Indonesia, Africa, the Middle East and Latin America to rise from 10% to 15% of sales. In Printing it plans to cut production staff by 30% and factory space by 40% by 2028 and to outsource hardware that needs no special technology.

A closer look at the financial trajectory of Amgen Inc. and Canon Inc. rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

Canon Inc.: Canon's sales fell from ~$27.3 billion (¥4,080.0 billion) in 2017, the first full year with Toshiba Medical, to ~$21.2 billion (¥3,160.2 billion) in 2020 as cameras and office printing shrank and the pandemic hit. They have grown every year since, reaching a record ~$31 billion (¥4,624.7 billion) in 2025 (+2.5%). Operating profit was ~$3.05 billion (¥455.4 billion) in 2025, a 9.8% margin, up from ~$1.87 billion (¥279.8 billion) in 2024, when a ~$1.11 billion (¥165.1 billion) goodwill impairment on the medical business cut net income to ~$1.07 billion (¥160.0 billion). Net income attributable to Canon Inc. more than doubled to ~$2.23 billion (¥332.1 billion) and EPS rose to ¥367.48. Canon paid a ¥160 dividend (42.9% payout), generated ~$1.6 billion (¥238.5 billion) of free cash flow and ended 2025 with ~$6.34 billion (¥946.2 billion) of interest-bearing debt, up from ~$4.45 billion (¥663.5 billion). By region, the Americas supplied 32% of 2025 sales, Europe 26%, Japan 21% and Asia and Oceania 21%. In July 2026, after record second-quarter sales, Canon guided to ~$32.2 billion (¥4,800.0 billion) of 2026 sales and ~$3.12 billion (¥465.0 billion) of operating profit.